Monocrotaline induced Pulmonary Hypertension (PAH)

Discovery

Pulmonary arterial hypertension (PAH) is one form of a broader condition known as pulmonary hypertension, which is high blood pressure in the lungs.

In rats, a single subcutaneous administration of monocrotaline induces increases in right ventricular (RV) pressure and pulmonary vascular modelling, approximately 4 weeks after monocrotaline administration.

Monocrotaline treated animals recorded a mean Fulton’s index of 0.35±0.04 versus vehicle treated animals of 0.20±0.04. Prophylactic and Therapeutic treatment of Sildenafil did not result in any changes in monocrotaline induced increases in Fulton's index.. Monocrotaline treated animals recorded a mean RVSP (mmHg) of 68.5±7.1 versus vehicle treated animals of 35.5±3.3. Prophylactic and Therapeutic treatment of Sildenafil significantly attenuates monocrotaline induced increase in RVSP.

Study Design
Species/Strain	SD rat
Model	Monocrotaline induced pulmonary arterial hypertension (PAH) rat model
Relevant Use	Assessing the efficacy of new compounds for PAH
Readouts Available	Bodyweights and Clinical Signs, invasive hemodynamic measurements (RVSP), Fulton’s index, histopathology (H&E, van Gieson)

Study data generated by Labcorp Huntingdon Pharmacology.

Molecule or Product Type

Biologics, Small Molecule

Models

Rat

Administration Routes

Dermal, Dietary, Gavage, Implant, Infusion, Inhalation, Intracranial, Intracutaneous, Intramuscular, Intranasal, Intraperitoneal, Intrathecal, Intratracheal, Intravenous, Ocular, Rectal, Subcutaneous, Transcortical, Vaginal

Regulatory

IND & CTA, NDA & BLA, Post-Market

Industry Market

Pharma

Phase

Discovery, Nonclinical

Related Models

Request a Quote

About our nonclinical animal research models: We provide the utmost care for our research animals and actively pursue advances in animal welfare. As well as ensuring the highest scientific, ethical and regulatory standards, selection of appropriate animal research models for development research is critical to developing safe and effective treatments, devices and products that protect and save lives. Just as we have ethical committee oversight for human trials, we have ethical committees overseeing all aspects of our global animal care and use programs. All of our core, nonclinical facilities are accredited by AAALAC. Learn more about our commitment to replacing, reusing and refining nonclinical research models.